Vertex Pharmaceuticals (VRTX) 8-K Entry into a Material Definitive Agreement

Exhibit 12.1

Vertex Pharmaceuticals Incorporated

Computation of Ratio of Earnings to Fixed Charges

(Amounts in thousands)

																Six Months Ended
	Year ended December 31,															June 30,
	2009			2008			2007			2006			2005			2010
Loss from continuing operations before cumulative effect of a change in accounting principle	$	(642,178	)	$	(459,851	)	$	(391,279	)	$	(207,937	)	$	(203,417	)	$	(365,277	)
Fixed charges:
Interest expense and amortization of deferred issuance costs	13,192			13,471			2,285			7,955			17,326			7,638
Appropriate rental obligations	17,827			14,901			13,520			15,938			14,736			9,765
Total fixed charges	$	31,019		$	28,372		$	15,805		$	23,893		$	32,062		$	17,403
Loss from continuing operations before cumulative effect of a change in accounting principle, plus fixed charges	$	(611,159	)	$	(431,479	)	$	(375,474	)	$	(184,044	)	$	(171,355	)	$	(347,874	)
Ratio of earnings to fixed charges	*			*			*			*			*			*

* Due to the Company’s loss from continuing operations before cumulative effect of a change in accounting principle, earnings were insufficent to cover fixed charges by $365,277,000 for the six months ended June 30, 2010 and earnings were insufficent to cover fixed charges by $642,178,000, $459,851,000, $391,279,000, $207,937,000 and $203,417,000, respectively, for the years ended December 31, 2009, 2008, 2007, 2006 and 2005.